The global Neurogenomics market size is expected to reach over $2.98 billion by 2030 at 14.7% CAGR, driven by the rising prevalence of neurological disorders.
Read MoreOral proteins and peptides market to reach $4.26 billion by 2030 at 22.2% cagr, driven by growing biopharmaceutical industry.
Read MoreGlobal Neurogenetic Testing market size is expected to reach $1.24 billion by 2030 at 11.9%, segmented as by microarray analysis, comparative genomic hybridization (cgh) microarray, single nucleotide polymorphism (snp) microarray
Read MoreOral mucositis treatment market to reach $3.44 billion by 2030 at 9.9% cagr, driven by increasing use of chemotherapy.
Read MoreGlobal Neurofibromatosis Type 1 market size is expected to reach $13.78 billion by 2030 at 9.2%, spontaneous (de novo) mutation driving the growth of the market
Read MoreOral hypoglycemic agents market to reach $75.62 billion by 2030 at 4.9% cagr, driven by rise in type 2 diabetes prevalence.
Read MoreGlobal Neurofibromatosis Treatment market size is expected to reach $27.75 billion by 2030 at 13.5%, segmented as , surgical interventions, medication for symptom management, genetic counseling
Read MoreOral contraceptive pills market to reach $61.05 billion by 2030 at 15.0% cagr, driven by rising healthcare expenditure.
Read MoreThe neurofeedback system market is projected to reach $2.61 billion by 2030, growing at 10.5% CAGR, driven by precision neurotherapy, AI-driven brain monitoring, and digital health integration.
Read MoreOral clinical nutrition supplement market to reach $18.2 billion by 2030 at 6.6% cagr, driven by growing awareness of preventive healthcare.
Read More
